117 related articles for article (PubMed ID: 20194244)
1. Cost-effectiveness of biologics in early rheumatoid arthritis.
Finckh A; Bansback N; Liang MH
Ann Intern Med; 2010 Mar; 152(5):333-4; author reply 334. PubMed ID: 20194244
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?
Boers M
Ann Intern Med; 2009 Nov; 151(9):668-9. PubMed ID: 19884628
[No Abstract] [Full Text] [Related]
3. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
Yen JH
Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
[No Abstract] [Full Text] [Related]
5. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
Pressman Lovinger S
JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
[No Abstract] [Full Text] [Related]
6. Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.
van den Hout WB
Nat Clin Pract Rheumatol; 2009 Feb; 5(2):78-9. PubMed ID: 19107111
[No Abstract] [Full Text] [Related]
7. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
8. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
Tsutani K; Igarashi A
Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis: out of touch with clinical reality?
Maetzel A
Arthritis Rheum; 2005 Feb; 53(1):3-4. PubMed ID: 15696549
[No Abstract] [Full Text] [Related]
10. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
Kulp W; Greiner W; Graf von der Schulenburg JM
Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
[TBL] [Abstract][Full Text] [Related]
12. The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
Bansback NJ; Young A; Brennan A
Rheumatology (Oxford); 2005 Jan; 44(1):3-4. PubMed ID: 15328422
[No Abstract] [Full Text] [Related]
13. Comparing model structures in cost-effectiveness analysis.
Russell LB
Med Decis Making; 2005; 25(5):485-6. PubMed ID: 16160203
[No Abstract] [Full Text] [Related]
14. Infliximab cost-effectiveness/safety?
Rothschild BM
Rheumatology (Oxford); 2003 Dec; 42(12):1572-3; author reply 1573-4. PubMed ID: 14645868
[No Abstract] [Full Text] [Related]
15. It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues.
O'Dell JR
Arthritis Rheum; 2007 Dec; 56(12):3884-6. PubMed ID: 18050217
[No Abstract] [Full Text] [Related]
16. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
Yuan Y; Trivedi D; Maclean R; Rosenblatt L
J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness analysis of drug therapies for rheumatoid arthritis.
Criswell LA; Such CL
J Rheumatol Suppl; 1996 Mar; 44():52-5. PubMed ID: 8833053
[TBL] [Abstract][Full Text] [Related]
18. The economics of treatment in early rheumatoid arthritis.
Bansback N; Marra CA; Finckh A; Anis A
Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
[TBL] [Abstract][Full Text] [Related]
19. When is switching warranted among biologic therapies in rheumatoid arthritis?
Reynolds A; Koenig AS; Bananis E; Singh A
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
Finucane KA; Archer CB
Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
[No Abstract] [Full Text] [Related]
[Next] [New Search]
